Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriage.
In order to examine the in vivo activity of BMY-28100, serial quantitative nasal cultures were taken from 52 nasal carriers of Staphylococcus aureus following administration of the antimicrobial. Nasal carriage rates and mean log titers decreased significantly during (days 2-4 and 5-8) and following (days 1-2 and 6-7) treatment. No change in antibiotic sensitivities was noted in follow-up isolates, and the MIC90 remained at 2mcg/ml. BMY-28100 demonstrated good in vivo activity against Staphylococcus aureus.
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030.
R L
RL
Atmar
M L
ML
Allen
J
J
Freiman
C
C
Kiefe
S
S
Ehrman
S B
SB
Greenberg
D000328:Adult; D002353:Carrier State / Q000188:drug therapy*; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009296:Nasal Cavity / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D000097670:Cefprozil
D002511:Cephalosporins; D000097670:Cefprozil